How would you manage persistent severe neutropenia from obinutuzumab in a 1st line CLL patient prior to venetoclax initiation?
Healthy elderly male with stage IV CLL, symptomatic, TP53 mutated, IGHV unmutated, bulky lymphadenopathy, first dose of Obinutuzumab resulted in ANC of 200, ALC went from 260k to zero.